Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
In: Annals of Oncology, Jg. 33 (2022), Heft 3, S. 355
academicJournal
Zugriff:
Titel: |
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
|
---|---|
Autor/in / Beteiligte Person: | Nitz, U.A. ; Gluz, O. ; Christgen, M. ; Grischke, E. M. ; Augustin, D. ; Kuemmel, S. ; Braun, M. ; Potenberg, J. ; Kohls, A. ; Krauss, K. ; Stefek, A. ; Schumacher, C. ; Forstbauer, H. ; Reimer, T. ; Fischer, H. ; Liedtke, C. ; Wuerstlein, R. ; Schumacher, J. ; Kates, R. ; Kreipe, H. ; Harbeck, N. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 33 (2022), Heft 3, S. 355 |
Veröffentlichung: | Elsevier BV, 2022 |
Medientyp: | academicJournal |
ISSN: | 0923-7534 |
DOI: | 10.1016/j.annonc.2021.12.008 |
Schlagwort: |
|
Sonstiges: |
|